Current Cardiology Reports

, 9:499 | Cite as

Residual risk in statin-treated patients: Future therapeutic options

  • Catherine Y. Campbell
  • Juan J. Rivera
  • Roger S. Blumenthal
Lipid Abnormalities and Cardiovascular Prevention

Abstract

Statin therapy for aggressive low-density lipoprotein cholesterol (LDL-C) reduction reduces cardiovascular morbidity and mortality. However, even on maximal statin therapy, high-risk patients have substantial residual risk of coronary heart disease (CHD). Certain subgroups, such as individuals with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), metabolic syndrome, or other comorbidities, have a particularly high residual risk. Patients at high risk for future CHD events often require multiple aggressive risk-reduction therapies (eg, antiplatelet agents, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blockade, cholesterol and/or diabetes management, and lifestyle interventions) to further lower their overall cardiovascular risk. For cholesterol management, combination therapy may be required to attain optimal levels of LDL-C, HDL-C, and non-HDL-C.

References and Recommended Reading

  1. 1.
    Shepherd J, Cobbe SM, Ford I, et al.:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group.N Engl J Med 1995,333:1301–1307.PubMedCrossRefGoogle Scholar
  2. 2.
    Downs JR, Clearfield M, Weis S, et al.:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA 1998,279:1615–1622.PubMedCrossRefGoogle Scholar
  3. 3.
    Sever PS, Dahlof B, Poulter NR, et al.:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet 2003,371:1149–1158.CrossRefGoogle Scholar
  4. 4.
    Scandinavian Simvastatin Survival Study Group:Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 1994,344:1383–1389.CrossRefGoogle Scholar
  5. 5.
    Sacks FM, Pfeffer MA, Moye LA, et al.:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators.N Engl J Med 1996,335:1001–1009.PubMedCrossRefGoogle Scholar
  6. 6.
    Shepherd J, Blauw GJ, Murphy MB, et al.:Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.Lancet 2002,360:1623–1630.PubMedCrossRefGoogle Scholar
  7. 7.
    LIPID Study Group:Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group.N Engl J Med 1998,339:1349–1357.CrossRefGoogle Scholar
  8. 8.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al.:Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.JAMA 2004,291:1071–1080.PubMedCrossRefGoogle Scholar
  9. 9.
    Of major importance LaRosa JC, Grundy SM, Waters DD, et al.:Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med 2005,352:1425–1435. The TNT study demonstrated that atorvastatin 80-mg daily is superior to atorvastatin 10-mg daily for reduction of cardiovascular events in patients with stable CHD. Mean LDL-C levels were 77 mg/dL with atorvastatin 80-mg daily and 101 mg/dL with atorvastatin-10 mg daily.PubMedCrossRefGoogle Scholar
  10. 10.
    Of importance Nissen SE, Nicholls SJ, Sipahi I, et al.:Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA 2006,295:1556–1565. The ASTEROID trial demonstrated that intensive therapy with rosuvastatin 40-mg daily results in regression of coronary atherosclerosis, as measured by intravascular ultrasound.PubMedCrossRefGoogle Scholar
  11. 11.
    Of major importance Cannon CP, Braunwald E, McCabe CH, et al.:Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med 2004,350:1495–1504. The PROVE-IT study demonstrated that intensive lipid lowering with atorvastatin 80-mg daily is superior to pravastatin 40-mg daily for reduction of cardiovascular events in patients hospitalized for ACS; event rates were 26% versus 22%.PubMedCrossRefGoogle Scholar
  12. 12.
    Grundy SM, Cleeman JI, Merz CN, et al.:Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation 2004,110:227–239.PubMedCrossRefGoogle Scholar
  13. 13.
    Briel M, Schwartz GG, Thompson PL, et al.Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.JAMA 2006,295:2046–2056.PubMedCrossRefGoogle Scholar
  14. 14.
    Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet 2002,360:7–22.CrossRefGoogle Scholar
  15. 15.
    Taylor AJ, Sullenberger LE, Lee HJ, et al.:Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.Circulation 2004,110:3512–3517.PubMedCrossRefGoogle Scholar
  16. 16.
    Deedwania P, Barter P, Carmena R, et al.:Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.Lancet 2006,368:919–928.PubMedCrossRefGoogle Scholar
  17. 17.
    Of importance Ridker PM, Cannon CP, Morrow D, et al.:C-reactive protein levels and outcomes after statin therapy.New Engl J Med 2005,352:20–28. In the PROVE-IT study, patients who achieved both a hsCRP level less than 1 mg/L and an LDL-C level less than 70 mg/dL had the lowest rate of recurrent events (1.9 per 100 person-years). In fact, achievement of these levels was more important than the choice of lipid-lowering therapy. Patients with high hsCRP levels had a high residual risk despite statin therapy; those with hsCRP levels above 2 mg/L had a rate of recurrent events of 4.6 per 100 person-years.PubMedCrossRefGoogle Scholar
  18. 18.
    Michos ED, Ardehali R, Blumenthal RS, et al.:Aspirin and clopidogrel resistance.Mayo Clin Proc 2006,81:518–526.PubMedGoogle Scholar
  19. 19.
    Of importance Nissen SE, Tuzcu EM, Schoenhagen P, et al.:Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.N Engl J Med 2005,352:29–38. In the REVERSAL study, patients with coronary artery disease were randomly assigned to receive atorvastatin 80-mg daily or pravastatin 40-mg daily. Patients with large reductions in hsCRP levels on statin therapy had slower rates of progression of atherosclerosis, even after adjustment for the decrease in lipid levels.PubMedCrossRefGoogle Scholar
  20. 20.
    Ridker PM; JUPITER Study Group:Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial Circulation 2003,108:2292–2297.PubMedCrossRefGoogle Scholar
  21. 21.
    Assmann G, Benecke H, Neiss A, et al.:Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy: results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation).Eur J Cardiovasc Prev Rehabil 2006,13:776–783.PubMedCrossRefGoogle Scholar
  22. 22.
    Ansell BJ, Fonarow GC, Maki KC, et al.:Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey.Am Heart J 2006,152:976–981.PubMedCrossRefGoogle Scholar
  23. 23.
    Bays HE, Davidson M, Jones MR, Abby SL:Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.Am J Cardiol 2006,97:1198–1205.PubMedCrossRefGoogle Scholar
  24. 24.
    Pearson TA, Denke MA, McBride PE, et al.:Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add-on to statin for effectiveness trial.Mayo Clin Proc 2006,81:1177–1185.PubMedCrossRefGoogle Scholar
  25. 25.
    Castro Cabezas M, de Vries JH, Van Oostrom AJ, et al.:Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins.J Am Diet Assoc 2006,106:1564–1569.PubMedCrossRefGoogle Scholar
  26. 26.
    Blair SN, Capuzzi DM, Gottlieb SO, et al.:Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.Am J Cardiol 2000,86:46–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Gordon DJ, Probstfield JL, Garrison RJ, et al.:High-density lipoprotein and cardiovascular disease: four prospective American studies.Circulation 1995,79:8–15.Google Scholar
  28. 28.
    King AC, Haskell WL, Young DR, et al.:Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years.Circulation 1995,91:2596–2604.PubMedGoogle Scholar
  29. 29.
    Maeda K, Noguchi Y, Fukui T:The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis.Prev Med 2003,37:283–290.PubMedCrossRefGoogle Scholar
  30. 30.
    Dattilo AM, Krisetherton PM:Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis.Am J Clin Nutr 1992,56:320–328.PubMedGoogle Scholar
  31. 31.
    Ellison RC, Zhang YQ, Qureshi MM, et al.:Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study.Am Heart J 2004,147:529–535.PubMedCrossRefGoogle Scholar
  32. 32.
    Gerasimova E, Perova N, Ozerova I, et al.:The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs Muscovites.Lipids 1991,26:261–265.PubMedCrossRefGoogle Scholar
  33. 33.
    Alderman JD, Pasternak RC, Sacks FM, et al.:Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high-density lipoprotein cholesterol and the cholesterol to high-density lipoprotein ratio.Am J Cardiol 1989,64:725–729.PubMedCrossRefGoogle Scholar
  34. 34.
    Prueksaritanont T, Zhao JJ, Ma B, et al.:Mechanistic studies on metabolic interactions between gemfibrozil and statins.J Pharmacol Exp Ther 2002,301:1042–1051.PubMedCrossRefGoogle Scholar
  35. 35.
    McKenney JM, Davidson MH, Shear CL, Revkin JH:Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.J Am Coll Cardiol 2006,48:1782–1790.PubMedCrossRefGoogle Scholar
  36. 36.
    Kastelein JJ, van Leuven SI, Burgess L, et al.:Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.N Engl J Med 2007,356:1620–1630.PubMedCrossRefGoogle Scholar
  37. 37.
    Nissen SE, Tardif JC, Nicholls SJ, et al.:Effect of torcetrapib on the progression of coronary atherosclerosis.N Engl J Med 2007,356:1304–1316.PubMedCrossRefGoogle Scholar
  38. 38.
    Bots ML, Visseren FL, Evans GW, et al.:Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.Lancet 2007,370:153–160.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Catherine Y. Campbell
  • Juan J. Rivera
  • Roger S. Blumenthal
    • 1
  1. 1.Johns Hopkins Ciccarone Preventive Cardiology CenterBaltimoreUSA

Personalised recommendations